Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium chloride dissociates in body fluids into sodium and chloride ions, which are major determinants of extracellular fluid osmolality and volume. It maintains electrolyte balance, nerve impulse transmission, and muscle contraction.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Treatment and prevention of sodium and chloride depletion (e.g., hyponatremia, hypochloremia),Fluid resuscitation in hypovolemia or shock,Diluent for intravenous medications,Maintenance of intravenous lines (saline locks),Irrigation of wounds and body cavities (e.g., during surgery),Management of hypercalcemia (promotes calcivresis),Diagnostic agent (e.g., in bronchoprovocation testing)
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Intravenous: 0.9% sodium chloride (normal saline) infusion at 50-100 m L/hour for maintenance; dose depends on indication (e.g., 500-1000 m L bolus for hypovolemia). Maximum rate: 1 L/hour in emergencies.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Variable and distribution-dependent; for acute changes, distribution half-life ~20 minutes; terminal half-life ~8-12 hours for total body sodium adjustment, clinically relevant for electrolyte correction
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Sodium and chloride ions are not metabolized; they are absorbed and distributed throughout the body, then excreted primarily by the kidneys. Regulation occurs via renal tubular reabsorption and excretion under hormonal control (e.g., aldosterone, ADH).
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Primarily renal (>90%) via glomerular filtration and tubular reabsorption; negligible biliary/fecal elimination (<1%)
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Negligible (<1%); not significantly protein-bound
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Approximately 0.6-0.7 L/kg (total body water); expands with extracellular fluid volume expansion
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Oral: 100% (passive absorption, no first-pass metabolism); intravenous: 100%
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
No dose adjustment required; use with caution in severe renal impairment due to fluid overload risk.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No dose adjustment required; monitor for fluid overload in cirrhosis with ascites.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Intravenous: Maintenance 100-120 m L/kg/day for first 10 kg, plus 50 m L/kg/day for next 10 kg, plus 20 m L/kg/day for each kg above 20; bolus 10-20 m L/kg over 30-60 minutes for hypovolemia.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Use lower infusion rates (e.g., 25-50 m L/hour maintenance) and monitor for fluid overload; adjust based on renal function and cardiovascular status.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
No FDA black box warning for sodium chloride.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Use with caution in patients with heart failure, renal impairment, cirrhosis with ascites, or edema (risk of fluid overload),Monitor serum electrolytes, fluid balance, and renal function during prolonged therapy,Avoid rapid infusion of large volumes, especially in patients with compromised cardiovascular or renal function,Use with caution in patients with hypertension (sodium load may increase blood pressure),Do not use solutions containing preservatives for irrigation of certain tissues (e.g., ophthalmic use),Risk of hypernatremia and hyperchloremia with excessive administration
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hypernatremia or hyperchloremia,Fluid overload (e.g., pulmonary edema, severe congestive heart failure),Severe renal impairment with oliguria or anuria (unless dialysis is being performed),Patients with elevated lactate levels (e.g., lactic acidosis) when used as a large volume resuscitation fluid (due to risk of hyperchloremic acidosis)
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
Avoid high-sodium foods (e.g., processed meats, canned soups, salty snacks) if receiving sodium chloride for hyponatremia or fluid management. No specific food interactions, but dietary sodium intake should be consistent with prescribed electrolyte goals.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Sodium chloride is an essential electrolyte and not teratogenic at physiological doses. No fetal risks identified in trimester 1, 2, or 3 when used appropriately. Excessive doses may cause maternal electrolyte imbalance, potentially affecting fetal homeostasis.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Sodium chloride is a normal component of breast milk. No adverse effects expected at therapeutic doses. M/P ratio not applicable as it is an endogenous substance. Compatible with breastfeeding.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
No dose adjustment required for normal replacement therapy. Pregnancy-induced plasma volume expansion may require higher maintenance doses in conditions like hypovolemia. In preeclampsia or eclampsia, careful monitoring and adjustment to avoid fluid overload. No specific pharmacokinetic changes necessitating dose alteration for basal requirements.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Administer 0.9% sodium chloride for volume expansion in hypovolemic patients; use with caution in heart failure or renal impairment due to risk of fluid overload. Hypertonic saline (3%) is reserved for severe hyponatremia with neurological symptoms; correct sodium slowly to avoid osmotic demyelination. Check serum sodium and osmolality before repeated doses.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Sodium chloride is salt; your dose depends on your blood sodium levels and hydration status.,You may experience swelling if you receive too much fluid; report shortness of breath or leg swelling.,This solution may be given through a vein; tell your nurse if you feel burning or pain at the IV site.,Do not consume extra salt in your diet unless directed; follow any dietary sodium restrictions from your doctor.,Monitor your weight daily if on long-term therapy, as sudden weight gain may indicate fluid retention.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
SODIUM CHLORIDE is a Electrolyte that works by Sodium chloride dissociates in body fluids into sodium and chloride ions, which are major determinants of extracellular fluid osmolality and volume. It maintains electrolyte balance, nerve impulse transmission, and muscle contraction.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM CHLORIDE is: Intravenous: 0.9% sodium chloride (normal saline) infusion at 50-100 m L/hour for maintenance; dose depends on indication (e.g., 500-1000 m L bolus for hypovolemia). Maximum rate: 1 L/hour in emergencies.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM CHLORIDE is classified as Category A/B. Sodium chloride is an essential electrolyte and not teratogenic at physiological doses. No fetal risks identified in trimester 1, 2, or 3 when used appropriately. Excessive doses m. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.